Chadi A. Calarge, MD

Personal Statement

The role mental wellbeing plays in overall health is increasingly appreciated, particularly during development. As such, I am part of a team that strives to optimize mental health in children and adolescents, including those suffering from other medical conditions. By comprehensively addressing the needs of children and teens, I hope to help them recover more rapidly and fully.

Clinical and Research Interests:

Working with children and adolescents with comorbid psychiatric and other medical conditions

Evaluating the safety of psychiatric medications following long-term use

Examining the links between the gut bacteria, the gut, and the brain

---

Education

,

,

Organizations

,

,

,

,

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Calarge CA, Devaraj S, Shulman RJ. Gut permeability and depressive symptom severity in unmedicated adolescents. J Affect Disord 2019 Mar 1;246:586-594. PubMed PMID: 30605877.

Calarge CA, Mills JA, Karaviti L, Teixeira AL, Zemel BS, Garcia JM. Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr 2018 Oct;201:245-251. PubMed PMID: 29958671; PubMed Central PMCID: PMC6153035.

Calarge CA, Mills JA, Janz KF, Burns TL, Schlechte JA, Coryell WH, Zemel BS. The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults. J Bone Miner Res. 2017 Dec;32(12):2367-2374. PubMed PMID: 28815738; PubMed Central PMCID: PMC5732069.

Calarge CA, Mills JA, Janz KF, Burns TL, Coryell WH, Zemel BS. Body Composition in Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors. Pediatrics 2017 Jul;140(1)PubMed PMID: 28759400; PubMed Central PMCID: PMC5495528.

Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol 2014 Apr;24(3):120-9. PubMed PMID: 24725198; PubMed Central PMCID: PMC3993060.

Calarge CA, Murry DJ, Ziegler EE, Arnold LE. Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol 2016 Jun;26(5):471-7. PubMed PMID: 26894929; PubMed Central PMCID: PMC4931353.

Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, Oltman CL, Azcarate-Peril MA, Kirby JR, Calarge CA. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry 2015 Oct 6;5:e652. PubMed PMID: 26440540; PubMed Central PMCID: PMC4930121.

View PubMed Publications:

https://www.ncbi.nlm.nih.gov/myncbi/chadi.calarge.1/bibliography/403886…